From Mila's Miracle to Mass Production: Julia Vitarello's Quest for Customized Genetic Medicines

In 2016, Julia Vitarello's daughter Mila was diagnosed with a devastating genetic disease caused by a unique mutation. In an unprecedented effort, researchers created a custom-made drug just for her—a so-called bespoke medicine. Now, Vitarello is launching a new biotech company aimed at producing such individualized therapies on a larger scale, learning from the challenges that led to the closure of her previous venture, EveryONE Medicines. Below, we explore the story behind this pioneering journey.

What was Mila's medicine and why was it considered bespoke?

Mila Vitarello suffers from a rare form of Batten disease caused by a single, unique mutation in the MFSD8 gene. Unlike traditional drugs tested on large populations, her therapy—dubbed milasen—was designed specifically to target her exact genetic error. This approach, known as n-of-1 therapy, creates a tailored antisense oligonucleotide that corrects the splicing defect in her cells. The drug was developed in record time and received FDA authorization for a single patient. Milasen's success, albeit temporary, proved that personalized genetic medicines are feasible, sparking hope for other ultra-rare conditions.

Why did Vitarello's first company, EveryONE Medicines, close?

EveryONE Medicines was founded to scale the production of customized therapies like milasen. However, it collapsed primarily due to regulatory uncertainty. The FDA released new guidance encouraging development of individualized treatments, but Vitarello stated it didn't go far enough to satisfy investors. The lack of a clear, predictable approval pathway made it risky for venture capital, especially for treatments that might only help one person. Without a solid return-on-investment model, funding dried up, forcing EveryONE to shut down. This setback taught Vitarello that both science and business frameworks need overhauling.

What is the new biotech company Vitarello is starting, and how will it differ?

The new venture remains unnamed, but its mission is to apply lessons from EveryONE's failure. Vitarello aims to create a more sustainable platform for individualized medicines by investing in automation and streamlined manufacturing. The company will focus on antisense oligonucleotides and potentially other modalities that can be rapidly adapted per patient. Crucially, it will work closely with regulators from day one to co-create a viable approval framework. By building a modular infrastructure, it hopes to drive down costs and timelines, making bespoke drugs commercially viable for many more patients—not just the ultra-wealthy.

What role does the FDA play in enabling or hindering these therapies?

The FDA has been both a pioneer and a bottleneck. It granted emergency authorization for milasen, but for broader adoption, the agency's 2022 draft guidance on n-of-1 trials fell short of establishing a clear pathway. The guidance suggested a data collection strategy but didn't specify how to achieve approval or marketing authorization for a one-patient drug. This ambiguity spooks investors, who need predictable endpoints. Vitarello's new company plans to engage with the FDA proactively to shape a more pragmatic regulatory environment—perhaps even advocating for a novel designation specifically for hyper-personalized therapies.

What are the biggest challenges in scaling bespoke medicines?

Scaling involves three major hurdles: manufacturing speed, regulatory complexity, and economic viability. Each drug is unique, requiring a custom synthesis process that currently takes months and costs millions. Automation and pre-approved “backbone” designs could accelerate production, but they need heavy upfront investment. Regulators demand rigorous safety data per patient, adding time. And without a profit model, pharma companies hesitate. Vitarello envisions a non-profit or hybrid structure where the cost-per-drug drops to tens of thousands rather than millions, possibly funded by a combination of philanthropy, government grants, and novel insurance models.

How does Mila's story inspire the broader field of precision medicine?

Mila's case demonstrated that rapid, individualized genomic medicine is not science fiction. It galvanized a movement now called N-of-1 therapy, inspiring projects like the N=1 Collaborative and similar biotechs. Her mother's relentless advocacy has pushed regulators, clinicians, and scientists to rethink one-size-fits-all drug development. Each subsequent attempt refines the process: better algorithms to design drugs, faster synthesis, and smarter trial designs. Mila's legacy is a world where those with vanishingly rare mutations might no longer be abandoned—a shift from treating diseases to treating individuals.

What is the timeline for Vitarello's new company, and who are her partners?

Vitarello announced in 2023 that she is seeking new funders and has collaborated with researchers from Boston Children's Hospital and the Broad Institute. She expects a proof-of-concept platform within two to three years. While specifics remain confidential, the company intends to initially target pediatric neurodegenerative diseases with known genetic causes. Partners include experts in antisense technology, regulatory science, and manufacturing. The goal is to produce the first batch of new bespoke drugs within five years, learning from EveryONE's missteps and building a more resilient business model.